Viewing Study NCT06131918



Ignite Creation Date: 2024-05-06 @ 7:46 PM
Last Modification Date: 2024-10-26 @ 3:13 PM
Study NCT ID: NCT06131918
Status: COMPLETED
Last Update Posted: 2023-11-14
First Post: 2023-08-25

Brief Title: Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy
Sponsor: Khyber Medical University Peshawar
Organization: Khyber Medical University Peshawar

Study Overview

Official Title: Assessment of Resveratrol Alpha Lipoic Acid and Superoxide Dismutase on Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients With Neuropathy A Randomized Control Trial
Status: COMPLETED
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: RCT
Brief Summary: Type 2 DM subjects having numbness tingling and paresthesia in hands and feet neuropathy will be recruited Screening of neuropathy will be done by Michigan screening instrument This will be followed by nerve conduction studies Specific blood parameters will also be checked The subjects will then be divided into four treatment arms Three groups will receive single drug and the fourth one will receive all the three drugs These will be given for four months Follow up will be done every month At the end of four months they will be assessed for any improvement in neuropathy by using Michigan neuropathy instrument and nerve conduction studies Blood parameters will also be measured again
Detailed Description: Type 2 DM subjects having numbness tingling and paresthesia in hands and feet neuropathy will be recruited They will be screened by Michigan neuropathy scale This is tool used for screening neuropathy Subjects having a score equal to or greater then 4 will be examined for further evaluation This will be followed by nerve conduction studies for objective assessment of neuropathy For inclusion criteria the test performed will be HbA1c CBC ESR RFTs and LFTs After screening the baseline levels of Superoxide radical Super oxide dismutase Glutathione peroxidase and Malonaldehyde will be measured The subjects will be randomly divided into four treatment arms Group A will receive Triple regime antioxidant therapy including Resveratrol 1500 mg two times a day Alpha lipoic acid 600 mg two times a day and Superoxide dismutase 250 mg once a day Group B will receive Resveratrol 1500mg BD Group C will be on Tab Alpha lipoic acid 600 mg BD and Group D will take Superoxide dismutase once a day The subjects will be kept blinded about the medication They will be followed every month in which their quality of life will be assessed using Nottingham health profile and neuropathy will be assessed by Michigan neuropathy scale At the end of four months blood tests will again be performed to check the levels of Superoxide radical Superoxide dismutase Glutathione peroxidase and Malonaldehyde NCS will be done to see any improvement in neuropathy

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None